|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBTF |
Gene summary for UBTF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBTF | Gene ID | 7343 |
| Gene name | upstream binding transcription factor | |
| Gene Alias | CONDBA | |
| Cytomap | 17q21.31 | |
| Gene Type | protein-coding | GO ID | GO:0001188 | UniProtAcc | P17480 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7343 | UBTF | LZE4T | Human | Esophagus | ESCC | 1.89e-18 | 3.99e-01 | 0.0811 |
| 7343 | UBTF | LZE5T | Human | Esophagus | ESCC | 1.55e-04 | 2.75e-01 | 0.0514 |
| 7343 | UBTF | LZE7T | Human | Esophagus | ESCC | 1.99e-02 | 3.37e-01 | 0.0667 |
| 7343 | UBTF | LZE8T | Human | Esophagus | ESCC | 1.14e-08 | 2.07e-01 | 0.067 |
| 7343 | UBTF | LZE20T | Human | Esophagus | ESCC | 7.30e-05 | 1.31e-01 | 0.0662 |
| 7343 | UBTF | LZE22T | Human | Esophagus | ESCC | 2.28e-03 | 3.99e-01 | 0.068 |
| 7343 | UBTF | LZE24T | Human | Esophagus | ESCC | 6.03e-15 | 5.29e-01 | 0.0596 |
| 7343 | UBTF | P1T-E | Human | Esophagus | ESCC | 2.22e-05 | 3.70e-01 | 0.0875 |
| 7343 | UBTF | P2T-E | Human | Esophagus | ESCC | 5.52e-48 | 8.17e-01 | 0.1177 |
| 7343 | UBTF | P4T-E | Human | Esophagus | ESCC | 4.65e-20 | 6.59e-01 | 0.1323 |
| 7343 | UBTF | P5T-E | Human | Esophagus | ESCC | 8.99e-25 | 5.14e-01 | 0.1327 |
| 7343 | UBTF | P8T-E | Human | Esophagus | ESCC | 9.20e-25 | 4.14e-01 | 0.0889 |
| 7343 | UBTF | P9T-E | Human | Esophagus | ESCC | 9.66e-08 | 3.34e-01 | 0.1131 |
| 7343 | UBTF | P10T-E | Human | Esophagus | ESCC | 3.32e-19 | 4.70e-01 | 0.116 |
| 7343 | UBTF | P11T-E | Human | Esophagus | ESCC | 1.20e-08 | 6.38e-01 | 0.1426 |
| 7343 | UBTF | P12T-E | Human | Esophagus | ESCC | 8.48e-38 | 7.11e-01 | 0.1122 |
| 7343 | UBTF | P15T-E | Human | Esophagus | ESCC | 3.78e-25 | 8.28e-01 | 0.1149 |
| 7343 | UBTF | P16T-E | Human | Esophagus | ESCC | 7.89e-28 | 5.13e-01 | 0.1153 |
| 7343 | UBTF | P17T-E | Human | Esophagus | ESCC | 4.70e-09 | 5.17e-01 | 0.1278 |
| 7343 | UBTF | P19T-E | Human | Esophagus | ESCC | 1.60e-05 | 5.81e-01 | 0.1662 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000635211 | Esophagus | ESCC | DNA-templated transcription, initiation | 86/8552 | 130/18723 | 1.88e-06 | 2.19e-05 | 86 |
| GO:00063602 | Esophagus | ESCC | transcription by RNA polymerase I | 42/8552 | 55/18723 | 3.41e-06 | 3.78e-05 | 42 |
| GO:00708973 | Esophagus | ESCC | transcription preinitiation complex assembly | 30/8552 | 36/18723 | 3.60e-06 | 3.95e-05 | 30 |
| GO:00063564 | Esophagus | ESCC | regulation of transcription by RNA polymerase I | 27/8552 | 34/18723 | 6.01e-05 | 4.62e-04 | 27 |
| GO:00459432 | Esophagus | ESCC | positive regulation of transcription by RNA polymerase I | 19/8552 | 23/18723 | 3.12e-04 | 1.85e-03 | 19 |
| GO:00063611 | Esophagus | ESCC | transcription initiation from RNA polymerase I promoter | 11/8552 | 13/18723 | 4.76e-03 | 1.85e-02 | 11 |
| GO:0070897 | Liver | Cirrhotic | transcription preinitiation complex assembly | 17/4634 | 36/18723 | 2.82e-03 | 1.63e-02 | 17 |
| GO:0006352 | Liver | HCC | DNA-templated transcription, initiation | 78/7958 | 130/18723 | 4.19e-05 | 4.11e-04 | 78 |
| GO:0006360 | Liver | HCC | transcription by RNA polymerase I | 36/7958 | 55/18723 | 4.94e-04 | 3.23e-03 | 36 |
| GO:0006356 | Liver | HCC | regulation of transcription by RNA polymerase I | 24/7958 | 34/18723 | 8.62e-04 | 5.13e-03 | 24 |
| GO:00708971 | Liver | HCC | transcription preinitiation complex assembly | 25/7958 | 36/18723 | 9.87e-04 | 5.71e-03 | 25 |
| GO:0045943 | Liver | HCC | positive regulation of transcription by RNA polymerase I | 16/7958 | 23/18723 | 8.04e-03 | 3.17e-02 | 16 |
| GO:00063522 | Oral cavity | OSCC | DNA-templated transcription, initiation | 74/7305 | 130/18723 | 2.56e-05 | 2.39e-04 | 74 |
| GO:00063563 | Oral cavity | OSCC | regulation of transcription by RNA polymerase I | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
| GO:00063601 | Oral cavity | OSCC | transcription by RNA polymerase I | 36/7305 | 55/18723 | 6.42e-05 | 5.22e-04 | 36 |
| GO:00459431 | Oral cavity | OSCC | positive regulation of transcription by RNA polymerase I | 18/7305 | 23/18723 | 1.47e-04 | 1.04e-03 | 18 |
| GO:00708972 | Oral cavity | OSCC | transcription preinitiation complex assembly | 24/7305 | 36/18723 | 7.18e-04 | 3.95e-03 | 24 |
| GO:0006361 | Oral cavity | NEOLP | transcription initiation from RNA polymerase I promoter | 5/2005 | 13/18723 | 8.62e-03 | 4.15e-02 | 5 |
| GO:00063561 | Prostate | Tumor | regulation of transcription by RNA polymerase I | 13/3246 | 34/18723 | 3.09e-03 | 1.63e-02 | 13 |
| GO:0071824 | Skin | AK | protein-DNA complex subunit organization | 38/1910 | 241/18723 | 4.43e-03 | 2.57e-02 | 38 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| UBTF | D | Stomach | Healthy | SCFD1,ADAM15,TGOLN2, etc. | 9.50e-03 |  |
| UBTF | A.X | Stomach | Healthy | SCFD1,ADAM15,TGOLN2, etc. | 2.17e-02 | |
| UBTF | PTC | Thyroid | Healthy | PPP1CC,TRIP11,CNPY2, etc. | 3.19e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBTF | SNV | Missense_Mutation | c.246C>A | p.Phe82Leu | p.F82L | P17480 | protein_coding | deleterious(0.04) | benign(0.164) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| UBTF | SNV | Missense_Mutation | novel | c.1964N>C | p.Ser655Thr | p.S655T | P17480 | protein_coding | tolerated(0.14) | benign(0.019) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| UBTF | SNV | Missense_Mutation | c.1974N>T | p.Lys658Asn | p.K658N | P17480 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UBTF | SNV | Missense_Mutation | novel | c.2176N>C | p.Glu726Gln | p.E726Q | P17480 | protein_coding | tolerated_low_confidence(0.17) | benign(0.013) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| UBTF | SNV | Missense_Mutation | c.1682N>C | p.Met561Thr | p.M561T | P17480 | protein_coding | tolerated(0.31) | benign(0.191) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD | |
| UBTF | insertion | Frame_Shift_Ins | novel | c.1334_1335insCGGCCGCGCA | p.Trp445CysfsTer9 | p.W445Cfs*9 | P17480 | protein_coding | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | |||
| UBTF | SNV | Missense_Mutation | rs758229343 | c.2122N>A | p.Asp708Asn | p.D708N | P17480 | protein_coding | tolerated_low_confidence(0.09) | probably_damaging(0.978) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UBTF | SNV | Missense_Mutation | novel | c.1551N>C | p.Met517Ile | p.M517I | P17480 | protein_coding | tolerated(0.17) | benign(0.007) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UBTF | SNV | Missense_Mutation | novel | c.1099N>A | p.Glu367Lys | p.E367K | P17480 | protein_coding | deleterious(0.03) | probably_damaging(0.913) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UBTF | SNV | Missense_Mutation | novel | c.1408A>G | p.Lys470Glu | p.K470E | P17480 | protein_coding | tolerated(0.13) | benign(0.345) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |